223 related articles for article (PubMed ID: 28511165)
1. Susceptibility of streptococcus pneumoniae to fluoroquinolones and macrolides in upper respiratory tract infections.
Mykhalko YO; Duhovych TV; Kish PP
Wiad Lek; 2017; 70(2):224-226. PubMed ID: 28511165
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.
Nicodemo AC; Mendes CM; Oplustil CP; Sinto S
Braz J Infect Dis; 2001 Apr; 5(2):50-2. PubMed ID: 11493408
[TBL] [Abstract][Full Text] [Related]
3. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
Ferrara AM
Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
[TBL] [Abstract][Full Text] [Related]
4. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
Fuller JD; Low DE
Clin Infect Dis; 2005 Jul; 41(1):118-21. PubMed ID: 15937772
[TBL] [Abstract][Full Text] [Related]
5. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
Appelbaum PC
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325
[TBL] [Abstract][Full Text] [Related]
6. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
Carter PL
Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
[TBL] [Abstract][Full Text] [Related]
7. In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.
Okamoto H; Miyazaki S; Tateda K; Ishii Y; Yamaguchi K
Antimicrob Agents Chemother; 2001 Nov; 45(11):3250-2. PubMed ID: 11600393
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of penicillin-resistant Streptococcus pneumoniae.
Cunha BA
Semin Respir Infect; 2002 Sep; 17(3):204-14. PubMed ID: 12226800
[TBL] [Abstract][Full Text] [Related]
9. [Antibacterial therapy of pneumococcal infections caused by drug resistant microorganisms].
Sidorenko SV
Antibiot Khimioter; 2002; 47(7):31-7. PubMed ID: 12516194
[No Abstract] [Full Text] [Related]
10. Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae?
Fenoll A; Aguilar L; Granizo JJ; Giménez MJ; Aragoneses-Fenoll L; Mendez C; Tarragó D
J Antimicrob Chemother; 2008 Dec; 62(6):1430-3. PubMed ID: 18819966
[TBL] [Abstract][Full Text] [Related]
11. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
[TBL] [Abstract][Full Text] [Related]
12. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
13. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
Jenkins SG; Brown SD; Farrell DJ
Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701
[TBL] [Abstract][Full Text] [Related]
14. Population antibiotic susceptibility for Streptococcus pneumoniae and treatment outcomes in common respiratory tract infections.
Furuno JP; Metlay JP; Harnett JP; Wilson J; Langenberg P; McGregor JC; Zhu J; Perencevich EN
Pharmacoepidemiol Drug Saf; 2006 Jan; 15(1):1-9. PubMed ID: 16136615
[TBL] [Abstract][Full Text] [Related]
15. The clinical impact of macrolide resistance in pneumococcal respiratory infections.
Garau J
Int J Antimicrob Agents; 2001; 18 Suppl 1():S33-8. PubMed ID: 11574193
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
17. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections.
Appelbaum PC
Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544
[TBL] [Abstract][Full Text] [Related]
18. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Sep; 50(37):800-4. PubMed ID: 11785571
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
[TBL] [Abstract][Full Text] [Related]
20. [A new antibiotic against respiratory tract infections. More power against pneumococci].
MMW Fortschr Med; 2001 Nov; 143(44):59. PubMed ID: 11732406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
